Positron emission tomography-based molecular imaging biomarkers may predict therapeutic response and survival in patients with metastatic castration-resistant prostate cancer, researchers say. READ MORE
Researchers compared the impact of hypofractionated radiation therapy and conventional radiation therapy on quality of life in patients with low-risk prostate cancer.
SBRT for men with prostate cancer results in shorter treatment times, low severe toxicity, and excellent cancer control rates.
Patients with metastatic castrate resistant prostate cancer treated with enzalutamide may experience central nervous system adverse events.
Active surveillance for patients with low-risk prostate cancer can provide similar quality of life to that of men living without cancer.
Positron emission tomography-based molecular imaging biomarkers may predict therapeutic response and survival in patients with metastatic castration-resistant prostate cancer, researchers say.
Survival among men with de novo metastatic prostate cancer has improved since the introduction of several systemic agents for the treatment of castrate-resistant disease.
Many patients with localized prostate cancer don’t understand the differences between their treatment options, a new study suggests.
A recent study compared the relative risk of cardiovascular ischemic events in patients with prostate cancer after surgical castration vs gonadotropin-releasing hormone agonist therapy.
Research in Review
Recent research has uncovered a new cause of treatment resistance in prostate cancer, which may improve targeted therapy efforts.
A combination regimen plus androgen-deprivation therapy prolongs OS and radiographic PFS in newly diagnosed patients with metastatic, castration-sensitive prostate cancer.
Recent research explored the potential of a subset of patients with intermediate-risk prostate cancer likely to benefit from active surveillance.
Quality improvements are needed to help optimize the implementation of active surveillance among urologists and practice settings.